No black box warning on record for Atorvaliq

As of the latest FDA labeling reviewed, Atorvaliq (ATORVALIQ) does not carry a black box warning. Standard warnings and precautions still apply — see the full Atorvaliq medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher ATORVALIQ dosage. Discontinue ATORVALIQ if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ATORVALIQ in patients experiencing an acute or serious c

No black box warning on record for Atorvaliq

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher ATORVALIQ dosage. Discontinue ATORVALIQ if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ATORVALIQ in patients experiencing an acute or serious c

Atorvaliq Black Box Warning

No black box warning on record for Atorvaliq

Other warnings & precautions

Atorvaliq Black Box Warning

No black box warning on record for Atorvaliq

Other warnings & precautions